British drugmaker GSK posted a sharp rise in net profit last year, driven by strong HIV, respiratory and cancer drug sales as the company moved past costly Zantac lawsuits.

Profit after tax jumped to £5.7 billion, more than double the previous year, while revenue climbed four per cent to £32.7 billion. Chief executive Luke Miels said speciality medicines powered the growth and expressed confidence the momentum will continue in 2026.

GSK expects low double-digit growth in speciality medicines this year but warned that vaccine and general medicine sales may fall. Shares rose about two per cent in early London trading, with the United States remaining the company’s biggest market.

READ ANOTHER STORY-https://classic97.net/messi-linked-with-shock-galatasaray-move/